Response to Long-term Vitamin D Therapy for Bone Disease in Children With Sickle Cell Disease
Overview
Affiliations
Patients with sickle cell disease (SCD) are at risk for bone fragility from multiple factors including vitamin D deficiency. To date, no studies have evaluated the efficacy and safety of long-term vitamin D therapy for bone disease in children with SCD. We report a cohort of 4 children with SCD found to have severe vitamin D deficiency, secondary hyperparathyroidism, and abnormal bone mineral density treated with monthly high-dose oral cholecalciferol over 2 years. All patients exhibited a positive response to therapy without hypervitaminosis D or hypercalcemia. Further studies are needed to standardize guidelines for optimal vitamin D dosing and prevention of toxicity.
Mulyana A, Rakhmawati W, Pramukti I, Lukman M, Wartakusumah R, Mediani H J Multidiscip Healthc. 2024; 17:3235-3246.
PMID: 39006879 PMC: 11246032. DOI: 10.2147/JMDH.S475371.
Hanna D, Kamal D, Fawzy H, Abd Elkhalek R Eur J Pediatr. 2024; 183(8):3347-3357.
PMID: 38743288 PMC: 11263414. DOI: 10.1007/s00431-024-05572-w.
Vitamin D supplementation for sickle cell disease.
Soe H, Abas A, Than N, Ni H, Singh J, Said A Cochrane Database Syst Rev. 2020; 5:CD010858.
PMID: 32462740 PMC: 7386793. DOI: 10.1002/14651858.CD010858.pub3.